208 related articles for article (PubMed ID: 27351213)
1. Overexpression of the oncostatin-M receptor in cervical squamous cell carcinoma is associated with epithelial-mesenchymal transition and poor overall survival.
Kucia-Tran JA; Tulkki V; Smith S; Scarpini CG; Hughes K; Araujo AM; Yan KY; Botthof J; Pérez-Gómez E; Quintanilla M; Cuschieri K; Caffarel MM; Coleman N
Br J Cancer; 2016 Jul; 115(2):212-22. PubMed ID: 27351213
[TBL] [Abstract][Full Text] [Related]
2. Anti-oncostatin M antibody inhibits the pro-malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma.
Kucia-Tran JA; Tulkki V; Scarpini CG; Smith S; Wallberg M; Paez-Ribes M; Araujo AM; Botthoff J; Feeney M; Hughes K; Caffarel MM; Coleman N
J Pathol; 2018 Mar; 244(3):283-295. PubMed ID: 29205362
[TBL] [Abstract][Full Text] [Related]
3. Tissue transglutaminase mediates the pro-malignant effects of oncostatin M receptor over-expression in cervical squamous cell carcinoma.
Caffarel MM; Chattopadhyay A; Araujo AM; Bauer J; Scarpini CG; Coleman N
J Pathol; 2013 Oct; 231(2):168-79. PubMed ID: 23765377
[TBL] [Abstract][Full Text] [Related]
4. Gain and overexpression of the oncostatin M receptor occur frequently in cervical squamous cell carcinoma and are associated with adverse clinical outcome.
Ng G; Winder D; Muralidhar B; Gooding E; Roberts I; Pett M; Mukherjee G; Huang J; Coleman N
J Pathol; 2007 Jul; 212(3):325-34. PubMed ID: 17516585
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of the oncostatin M receptor in cervical squamous cell carcinoma cells is associated with a pro-angiogenic phenotype and increased cell motility and invasiveness.
Winder DM; Chattopadhyay A; Muralidhar B; Bauer J; English WR; Zhang X; Karagavriilidou K; Roberts I; Pett MR; Murphy G; Coleman N
J Pathol; 2011 Nov; 225(3):448-62. PubMed ID: 21952923
[TBL] [Abstract][Full Text] [Related]
6. Virus and Host Events in Squamous Carcinogenesis.
Coleman N
Keio J Med; 2016; 65(4):78. PubMed ID: 28025425
[TBL] [Abstract][Full Text] [Related]
7. Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma.
Caffarel MM; Coleman N
J Pathol; 2014 Mar; 232(4):386-90. PubMed ID: 24659184
[TBL] [Abstract][Full Text] [Related]
8. Oncostatin M receptor, positively regulated by SP1, promotes gastric cancer growth and metastasis upon treatment with Oncostatin M.
Yu Z; Li Z; Wang C; Pan T; Chang X; Wang X; Zhou Q; Wu X; Li J; Zhang J; Liu B; Zhu Z; Su L
Gastric Cancer; 2019 Sep; 22(5):955-966. PubMed ID: 30778797
[TBL] [Abstract][Full Text] [Related]
9. Annexin A2-STAT3-Oncostatin M receptor axis drives phenotypic and mesenchymal changes in glioblastoma.
Matsumoto Y; Ichikawa T; Kurozumi K; Otani Y; Fujimura A; Fujii K; Tomita Y; Hattori Y; Uneda A; Tsuboi N; Kaneda K; Makino K; Date I
Acta Neuropathol Commun; 2020 Apr; 8(1):42. PubMed ID: 32248843
[TBL] [Abstract][Full Text] [Related]
10. Potent EMT and CSC Phenotypes Are Induced By Oncostatin-M in Pancreatic Cancer.
Smigiel JM; Parameswaran N; Jackson MW
Mol Cancer Res; 2017 Apr; 15(4):478-488. PubMed ID: 28053127
[TBL] [Abstract][Full Text] [Related]
11. Oncostatin-M and OSM-Receptor Feed-Forward Activation of MAPK Induces Separable Stem-like and Mesenchymal Programs.
Polak KL; Tamagno I; Parameswaran N; Smigiel J; Chan ER; Yuan X; Rios B; Jackson MW
Mol Cancer Res; 2023 Sep; 21(9):975-990. PubMed ID: 37310811
[TBL] [Abstract][Full Text] [Related]
12. Expression of short-form oncostatin M receptor as a decoy receptor in lung adenocarcinomas.
Chen D; Chu CY; Chen CY; Yang HC; Chiang YY; Lin TY; Chiang IP; Chuang DY; Yu CC; Chow KC
J Pathol; 2008 Jul; 215(3):290-9. PubMed ID: 18491353
[TBL] [Abstract][Full Text] [Related]
13. Box 2 region of the oncostatin M receptor determines specificity for recruitment of Janus kinases and STAT5 activation.
Hintzen C; Evers C; Lippok BE; Volkmer R; Heinrich PC; Radtke S; Hermanns HM
J Biol Chem; 2008 Jul; 283(28):19465-77. PubMed ID: 18430728
[TBL] [Abstract][Full Text] [Related]
14. Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth.
Geethadevi A; Nair A; Parashar D; Ku Z; Xiong W; Deng H; Li Y; George J; McAllister DM; Sun Y; Kadamberi IP; Gupta P; Dwinell MB; Bradley WH; Rader JS; Rui H; Schwabe RF; Zhang N; Pradeep S; An Z; Chaluvally-Raghavan P
Cancer Res; 2021 Oct; 81(20):5336-5352. PubMed ID: 34380633
[TBL] [Abstract][Full Text] [Related]
15. Heterocellular OSM-OSMR signalling reprograms fibroblasts to promote pancreatic cancer growth and metastasis.
Lee BY; Hogg EKJ; Below CR; Kononov A; Blanco-Gomez A; Heider F; Xu J; Hutton C; Zhang X; Scheidt T; Beattie K; Lamarca A; McNamara M; Valle JW; Jørgensen C
Nat Commun; 2021 Dec; 12(1):7336. PubMed ID: 34921158
[TBL] [Abstract][Full Text] [Related]
16. Stat3-coordinated Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain oncostatin M-driven epithelial-mesenchymal transition.
Guo L; Chen C; Shi M; Wang F; Chen X; Diao D; Hu M; Yu M; Qian L; Guo N
Oncogene; 2013 Nov; 32(45):5272-82. PubMed ID: 23318420
[TBL] [Abstract][Full Text] [Related]
17. Oncostatin M acting via OSMR, augments the actions of IL-1 and TNF in synovial fibroblasts.
Le Goff B; Singbrant S; Tonkin BA; Martin TJ; Romas E; Sims NA; Walsh NC
Cytokine; 2014 Aug; 68(2):101-9. PubMed ID: 24767864
[TBL] [Abstract][Full Text] [Related]
18. ΔNp63α attenuates tumor aggressiveness by suppressing miR-205/ZEB1-mediated epithelial-mesenchymal transition in cervical squamous cell carcinoma.
Zhao W; Wang H; Han X; Ma J; Zhou Y; Chen Z; Zhou H; Xu H; Sun Z; Kong B; Fang H
Tumour Biol; 2016 Aug; 37(8):10621-32. PubMed ID: 26864590
[TBL] [Abstract][Full Text] [Related]
19. Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer.
West NR; Murray JI; Watson PH
Oncogene; 2014 Mar; 33(12):1485-94. PubMed ID: 23584474
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6-induced epithelial-mesenchymal transition through signal transducer and activator of transcription 3 in human cervical carcinoma.
Miao JW; Liu LJ; Huang J
Int J Oncol; 2014 Jul; 45(1):165-76. PubMed ID: 24806843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
